Brief: Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy
12/12/2025 13:45
Dec 12 (Reuters) - Cytokinetics Inc CYTK.O: CYTOKINETICS ANNOUNCES POSITIVE CHMP OPINION OF MYQORZO® (AFICAMTEN) FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY CYTOKINETICS INC - EUROPEAN COMMISSION FINAL DECISION EXPECTED IN Q1 2026 Source text: ID:nGNXbM3K8v Further company coverage: CYTK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech